The real-life effect of catechol-O-methyltransferase inhibition on non-motor symptoms in levodopa-treated Parkinson’s disease: opicapone versus entacapone
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
Online-Ressource, 1 online resource.
- Sprache
-
Englisch
- Erschienen in
-
The real-life effect of catechol-O-methyltransferase inhibition on non-motor symptoms in levodopa-treated Parkinson’s disease: opicapone versus entacapone ; volume:130 ; number:7 ; day:10 ; month:4 ; year:2023 ; pages:925-930 ; date:7.2023
Journal of neural transmission ; 130, Heft 7 (10.4.2023), 925-930, 7.2023
- Urheber
-
Leta, Valentina
Wamelen, Daniel J. van
Aureli, Federico
Metta, Vinod
Trivedi, Dhaval
Cortelli, Pietro
Rodriguez-Blazquez, Carmen
Rizos, Alexandra
Chaudhuri, K. Ray
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1007/s00702-023-02603-y
- URN
-
urn:nbn:de:101:1-2023092710294620473521
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:58 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Leta, Valentina
- Wamelen, Daniel J. van
- Aureli, Federico
- Metta, Vinod
- Trivedi, Dhaval
- Cortelli, Pietro
- Rodriguez-Blazquez, Carmen
- Rizos, Alexandra
- Chaudhuri, K. Ray
- SpringerLink (Online service)
Ähnliche Objekte (12)
Gender differences in non-motor fluctuations in Parkinson’s disease
Non-motor symptoms in newly diagnosed Parkinson’s disease patients
Screening for non-motor symptoms in Egyptian patients with Parkinson’s disease
NMDA antagonists for treating the non-motor symptoms in Parkinson’s disease
Diagnostic prediction model for levodopa-induced dyskinesia in Parkinson’s disease
Modulatory Effects of Levodopa on Cerebellar Connectivity in Parkinson’s Disease
Embelin and levodopa combination therapy for improved Parkinson’s disease treatment
Gut bacterial deamination of residual levodopa medication for Parkinson’s disease
Genetic meta-analysis of levodopa induced dyskinesia in Parkinson’s disease
Motor and non-motor outcomes in patients with advanced Parkinson’s disease treated with levodopa/carbidopa intestinal gel: final results of the GREENFIELD observational study
Nonmotor symptom burden grading as predictor of cognitive impairment in Parkinson’s disease
Microstructure predicts non-motor outcomes following deep brain stimulation in Parkinson’s disease
Gender differences in non-motor fluctuations in Parkinson’s disease
Non-motor symptoms in newly diagnosed Parkinson’s disease patients
Screening for non-motor symptoms in Egyptian patients with Parkinson’s disease
NMDA antagonists for treating the non-motor symptoms in Parkinson’s disease
Diagnostic prediction model for levodopa-induced dyskinesia in Parkinson’s disease
Modulatory Effects of Levodopa on Cerebellar Connectivity in Parkinson’s Disease
Embelin and levodopa combination therapy for improved Parkinson’s disease treatment
Gut bacterial deamination of residual levodopa medication for Parkinson’s disease
Genetic meta-analysis of levodopa induced dyskinesia in Parkinson’s disease
Motor and non-motor outcomes in patients with advanced Parkinson’s disease treated with levodopa/carbidopa intestinal gel: final results of the GREENFIELD observational study
Nonmotor symptom burden grading as predictor of cognitive impairment in Parkinson’s disease
Microstructure predicts non-motor outcomes following deep brain stimulation in Parkinson’s disease
Gender differences in non-motor fluctuations in Parkinson’s disease
Non-motor symptoms in newly diagnosed Parkinson’s disease patients
Screening for non-motor symptoms in Egyptian patients with Parkinson’s disease
NMDA antagonists for treating the non-motor symptoms in Parkinson’s disease
Diagnostic prediction model for levodopa-induced dyskinesia in Parkinson’s disease
Modulatory Effects of Levodopa on Cerebellar Connectivity in Parkinson’s Disease
Embelin and levodopa combination therapy for improved Parkinson’s disease treatment
Gut bacterial deamination of residual levodopa medication for Parkinson’s disease
Genetic meta-analysis of levodopa induced dyskinesia in Parkinson’s disease
Motor and non-motor outcomes in patients with advanced Parkinson’s disease treated with levodopa/carbidopa intestinal gel: final results of the GREENFIELD observational study
Nonmotor symptom burden grading as predictor of cognitive impairment in Parkinson’s disease